ストックスクリーナーアプリを入手
10.17
0.10%
-0.010
前日終値:
$10.18
開ける：
$10.19
24時間の取引高:
1.06M
Relative Volume:
0.91
時価総額：
$383.50M
収益：
$127.70M
当期純損益:
$-121.25M
株価収益率:
-3.2286
EPS:
-3.15
ネットキャッシュフロー:
$-120.32M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
+53.63%
6か月 パフォーマンス:
+22.24%
1年 パフォーマンス:
-39.46%
1日の値動き範囲:
$10.14
$10.31
1週間の範囲:
$9.895
$10.31
52週間の値動き範囲:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
ITOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.17 | 383.50M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-05-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-13 | 開始されました | Wells Fargo | Overweight |
| 2021-05-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | SVB Leerink | Outperform |
| 2020-08-18 | 開始されました | Wedbush | Outperform |
すべてを表示
Iteos Therapeutics Inc (ITOS) 最新ニュース
Squarepoint Ops LLC Sells 18,686 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Director David Hallal Sells 114,682 Shares of ITeos Therapeutics Inc (ITOS) - GuruFocus
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock - Investing.com Australia
iTeos Therapeutics Executives Sell Significant Shares - TradingView
Nuveen Asset Management LLC Trims Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iteos therapeutics announces board resignation - Investing.com
iteos therapeutics announces board resignation By Investing.com - Investing.com UK
Tim Van Hauwermeiren Resigns from iTeos Board - TipRanks
Deutsche Bank AG Sells 14,418 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Long Term Trading Analysis for (ITOS) - news.stocktradersdaily.com
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Q2 EPS Forecast for iTeos Therapeutics Decreased by Analyst - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Position Increased by Ameriprise Financial Inc. - Defense World
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know - MSN
Wedbush Lowers Earnings Estimates for iTeos Therapeutics - Defense World
Rx Rundown: Novartis, iTeos Therapeutics, Moderna and more - Medical Marketing and Media
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
All Over For iTeos But Applause For Plan To Return Cash Fast - insights.citeline.com
iTeos to shut down operations after TIGIT setback and GSK exit - The Pharma Letter
iTeos Therapeutics (NASDAQ:ITOS) Receives “Equal Weight” Rating from Wells Fargo & Company - Defense World
iTeos Therapeutics to wind down operations, explore asset sales By Investing.com - Investing.com South Africa
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
iTeos Therapeutics (NASDAQ:ITOS) Lowered to “Neutral” Rating by Wedbush - Defense World
Wedbush cuts iTeos stock rating, raises PT to $12 from $10 - Investing.com Canada
Drug developer iTeos to shut down operations after cancer therapy setback - 1470 & 100.3 WMBD
Cancer drugmaker iTeos to shut down - BioPharma Dive
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’ - Investing.com India
iTeos Therapeutics stock surges on wind-down news By Investing.com - Investing.com Canada
Watertown immuno-oncology biotech winds down operations - The Business Journals
iTeos Therapeutics (ITOS) Downgraded by Wells Fargo with Revised Price Target | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Amid Operational Changes | ITOS Stock News - GuruFocus
ITeos Therapeutics (ITOS) Sees Downgrade and Target Price Cut | - GuruFocus
ITeos Therapeutics (ITOS) Sees Downgrade and Target Price Cut | ITOS Stock News - GuruFocus
iTeos Therapeutics stock surges on wind-down news - Investing.com
ITeos Therapeutics (ITOS) Receives Analyst Downgrade from Wedbus - GuruFocus
iTeos Therapeutics (ITOS) Downgraded as Company Plans Operationa - GuruFocus
Wedbush Downgrades iTeos Therapeutics (ITOS) Rating to Neutral | - GuruFocus
I Teos Therapeutics Inc Expected Severance Costs Of $21.8 Million To $24.7 Million - marketscreener.com
ITeos Therapeutics (ITOS) Receives Analyst Downgrade from Wedbush | ITOS Stock News - GuruFocus
Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10 - marketscreener.com
iTeos Therapeutics (ITOS) to Cease Operations and Explore Strate - GuruFocus
iTeos Therapeutics (ITOS) Shares Surge on Plans to Cease Operati - GuruFocus
iTeos Therapeutics (ITOS) to Wind Down Operations, Focus on Shar - GuruFocus
Drug developer iTeos winds down after cancer therapy setback - marketscreener.com
iTeos Therapeutics (ITOS) to Wind Down Operations, Focus on Shareholder Value | ITOS Stock News - GuruFocus
iTeos Therapeutics Announces Strategic Wind Down Plan - TipRanks
ITeos Therapeutics to Wind Down Operations - marketscreener.com
iTeos stock surges on plans to end operations (ITOS:NASDAQ) - Seeking Alpha
iTeos Therapeutics to wind down operations, explore asset sales - Investing.com
iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewswire
iTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value - Nasdaq
Iteos Therapeutics Inc (ITOS) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):